Squarepoint Ops LLC Has $11.30 Million Stake in Ultragenyx Pharmaceutical Inc. $RARE

Squarepoint Ops LLC reduced its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 23.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 338,368 shares of the biopharmaceutical company’s stock after selling 106,171 shares during the quarter. Squarepoint Ops LLC’s holdings in Ultragenyx Pharmaceutical were worth $11,298,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Ultragenyx Pharmaceutical by 14.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after buying an additional 29,984 shares during the period. Creative Planning acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $454,000. American Century Companies Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $366,000. M&T Bank Corp lifted its holdings in shares of Ultragenyx Pharmaceutical by 19.7% during the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 1,192 shares during the period. Finally, Amundi boosted its position in shares of Ultragenyx Pharmaceutical by 1,560.4% during the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock valued at $3,913,000 after acquiring an additional 93,189 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $14.31 on Thursday. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -2.45 and a beta of 0.31. The firm’s 50-day simple moving average is $26.73 and its 200-day simple moving average is $24.88. Ultragenyx Pharmaceutical Inc. has a twelve month low of $13.81 and a twelve month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.32. The firm had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm’s quarterly revenue was up 28.5% on a year-over-year basis. During the same period last year, the firm posted ($1.17) EPS. As a group, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wedbush lowered their target price on shares of Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, September 3rd. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. William Blair downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Thursday, September 3rd. Citigroup lowered their price objective on Ultragenyx Pharmaceutical from $58.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. Finally, Wells Fargo & Company cut Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $50.00 to $18.00 in a report on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $36.63.

Insider Buying and Selling

In other news, Director Corsee Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the transaction, the director owned 21,095 shares in the company, valued at approximately $528,429.75. The trade was a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Karah Parschauer sold 1,899 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the transaction, the executive vice president directly owned 94,462 shares in the company, valued at $2,325,654.44. The trade was a 1.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 4,060 shares of company stock valued at $99,106 in the last quarter. 5.20% of the stock is currently owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.